ArticleFrontiers in oncology2021
Characterization of the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma Using Imaging Mass Cytometry.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Network-based single-cell analysis identifies a proliferative GZMBJournal of translational medicine · 2026Article
- The role of the tumor microenvironment in drug resistance acquisition in lung squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2026Review
- Simultaneous immunomodulation and epithelial-to-mesenchymal transition drives lung adenocarcinoma progression.bioRxiv : the preprint server for biology · 2025Article
- From surfing to diving into the tumor microenvironment through multiparametric imaging mass cytometry.Frontiers in immunology · 2025Review
- Fluorescence Lifetime Multiplexing (FLEX) for simultaneous high dimensional spatial biology in 3D.Communications biology · 2024Article
- Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer.Cancer discovery · 2024Article
- Multiplexed Imaging Mass Cytometry Analysis in Preclinical Models of Pancreatic Cancer.International journal of molecular sciences · 2024Article
- Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies.Cancers · 2023Review
- Using Artificial Intelligence to Identify Tumor Microenvironment Heterogeneity in Non-Small Cell Lung Cancers.Laboratory investigation; a journal of technical methods and pathology · 2023Article
- RGN as a prognostic biomarker with immune infiltration and ceRNA in lung squamous cell carcinoma.Scientific reports · 2023Article
- Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy.Seminars in immunopathology · 2023Review
- Revisiting transplant immunology through the lens of single-cell technologies.Seminars in immunopathology · 2023Review
- Dissecting the Immunological Profiles inCancers · 2022Article
- Spatially variant immune infiltration scoring in human cancer tissues.NPJ precision oncology · 2022Article
- Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases.Journal of neurosurgery. Case lessons · 2022Article
- Review
- Advances in mass cytometry and its applicability to digital pathology in clinical-translational cancer research.Advances in laboratory medicine · 2022Review
- Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report.Frontiers in immunology · 2022Article
- Characteristic of Molecular Subtypes in Lung Squamous Cell Carcinoma Based on Autophagy-Related Genes and Tumor Microenvironment Infiltration.Journal of oncology · 2022Article
- Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung squamous cell carcinoma (LUSC) is a major subtype of non-small cell lung cancer. The tumor immune microenvironment (TIME) affects the anti-tumor immune response and the patient's prognosis, although the TIME in LUSC patients is incompletely understood.
methodsWe retrospectively collected surgical specimens from patients with previously untreated primary LUSC. Histopathological examination was used to identify tumor regions and adjacent regions, and imaging mass cytometry was used to characterize the immune cells in those regions. The results were compared between regions and between patients.
resultsWe identified heterogeneity in the TIME on comparing different patients with LUSC, although the tumor region and adjacent region both exhibited an immune response to the tumor. The TIME typically included a large number of infiltrating and activated T-cells, especially CD8
conclusionsThe TIME of LUSC appears to be immunogenic and heterogenous, with predominant infiltration of activated CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.